CD22 and non-Hodgkin lymphoma: CD22 (Siglec-2), which is pivotal for B cell activation, serves as a therapeutic target and a reliable biomarker for B cell-derived non-Hodgkin’s lymphoma and some autoimmune disorders [134], and patients exhibiting elevated CD22 expression derive enhanced survival benefits from CD22-targeted therapeutics [135].